Study S000823

Potential Impact of Oral Semaglutide on Coronary Artery Disease Progression Following Acute Coronary Syndrome: The POST-ACS Study

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT05322200
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE4
Masking: TRIPLE
Status: UNKNOWN
Enrollment: 140
Start: 2022-08-31
Primary completion: 2024-04-28
Lead sponsor: Swansea Bay University Health Board
Conditions: Diabetes Mellitus; Acute Coronary Syndrome; Coronary Artery Disease
Interventions: RADIATION:A computerized tomography (CT) coronary angiogram; PROCEDURE:Vicorder (Skidmore medical, UK); OTHER:Blood tests for inflammation and oxidative stress markers
Results posted: FALSE
Individual participant data sharing: NO

Registered primary outcomes

Compare the regression of vulnerable coronary plaque (necrotic core) assessed using histologically validated "Plaque Maps" derived from CT Coronary angiography in patients with raised HbA1c admitted with ACS and treated with oral Semaglutide or placebo. [12 months]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.